TheTechno Optimist.

SimpleScreen CRCFreenome—FDA approves Freenome's SimpleScreen CRC blood test; Abbott to market it in the USFreenome—Freenome lists on Nasdaq through a SPAC merger, raising about $310M

Freenome

Blood tests for cancer screening, SimpleScreen CRC

USpublicfreenome.com (opens freenome.com)Checked 11 Oct

The brief

Analyst view
  • SimpleScreen CRC: FDA approved 27 Jul 2026 for average-risk adults 45+, the second blood test after Guardant's Shield.
  • Abbott (which bought Exact Sciences) sells it in the US; deal worth up to $885M to Freenome.
  • Listed on Nasdaq (FRNM) in July 2026 via a SPAC, raising about $310M.
Primer